Dermatology Times Newsletter

To view this email as a web page, click here.

You’re reading the latest from Dermatology Times. Our mission is to provide you with clinical insights that expand your expertise and advance your practice. Connect with us on Twitter and Facebook for daily updates.

More data needed to back SLNB for melanoma

Sentinel lymph node biopsy (SLNB) has classically been performed for regional disease control and to hopefully prevent disease metastasis; however, according to this expert, there has not been any good evidence to support this practice.

Melanoma therapeutics on the horizon

This pipeline report presents insights into drugs currently in phase 2, phase 3 or recently approved for the treatment of melanoma.

Adjunct molecular tests aid melanoma diagnosis

Molecular assays have been proven to assist in the diagnosis and prognosis of malignant melanoma. One expert expects that these molecular assays will play a central role in the future treatment and management of malignant melanoma.

Mean graded improvement of 55.6% for Poikiloderma of Civatte

In Part 2 of this podcast series, featured physician Eric Bernstein, MD, MSE, discusses a study of patients with Poikiloderma of Civatte who were treated with the Vbeam Prima Laser.

Listen now.

From our Latest Issue

Positive workplaces improve patient experiences

How to advocate for the future of dermatology

Basal cell carcinoma treatments on the horizon

JOB OPPORTUNITIES

CA - Integrated Dermatology

CO-Integrated Dermatology

CT - Integrated Dermatology

District of Columbia-Integrated Dermatology

MA - Integrated Dermatology

MD - Integrated Dermatology

MS - Integrated Dermatology

National - Integrated Dermatology

NJ - Integrated Dermatology

NJ - Practice for Sale

NV - Integrated Dermatology

VA - Integrated Dermatology

VT - Integrated Dermatology

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.